UP!
 |
|
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: ACTG |
| Industry | Patent Licensing & Monetization |
| Founded | 1993 |
| Headquarters | Newport Beach, California, USA |
|
Key people
|
Marvin Key, CEO Clayton J. Haynes, CFO |
| Subsidiaries | Acacia Research Group LLC |
| Website | acaciaresearch.com |
Acacia Research Corporation is an American company based in Newport Beach, California, that works to license patents and perform relevant legal action such as dealing with patent infringement.
Acacia is sometimes referred to as a non-practicing entity because the company derives revenue from licenses and lawsuits rather than from building products. According to the company, it has returned over $705,000,000 to patent owners. The corporation creates a subsidiary company for each set of patents it enforces. Currently, 95% of the company's business involves partnering with inventors and patent holders. It currently has 180 known subsidiaries and 257 active cases as of September 2014, four of which are not through a subsidiary.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-14 | Future report Set alerts | |
| Q2 2022 | 2022-08-11 | -0.60 | -0.60 |
| Q1 2022 | 2022-05-12 | -0.99 | -0.99 |
| Q4 2021 | 2022-03-31 | -0.52 | -0.52 |
| Q3 2021 | 2021-11-15 | -0.26 | -0.26 |
| Q2 2021 | 2021-08-16 | 0.26 | 0.26 |
| Q1 2021 | 2021-05-17 | -2.68 | -2.68 |
| Q4 2020 | 2021-03-29 | 0.00 | 0.00 |
| Q3 2020 | 2020-11-09 | -0.12 | -0.12 |
| Q2 2020 | 2020-08-10 | -0.11 | -0.11 |
| 2016-05-23 | Upgrade | Northland Securities | Market Perform to Outperform | $5.20 to $7.00 |
| 2016-01-05 | Downgrade | Barclays | Equal Weight to Underweight | $12.00 to $4.00 |
| 2016-01-05 | Downgrade | Barclays PLC | Equal Weight to Underweight | $12.00 to $4.00 |
| 2015-12-28 | Downgrade | Northland Securities | Hold | |
| 2015-12-23 | Lower Price Target | Lake Street Capital | Buy | $12.00 to $6.50 |
| 2015-12-22 | Downgrade | Northland Securities | Outperform to Market Perform | $5.40 |
| 2015-08-20 | Lower Price Target | Barclays | Equal Weight | $15.00 to $12.00 |
| 2015-04-23 | Set Price Target | Cowen and Company | Outperform to Buy | $20.00 |
| 2015-02-20 | Lower Price Target | JPMorgan Chase & Co. | Overweight | $17.00 to $15.00 |
| 2015-02-20 | Set Price Target | Barclays | Hold | $20.00 to $15.00 |
| 2015-02-20 | Lower Price Target | Cowen and Company | Outperform | $24.00 to $20.00 |
| 2015-01-21 | Lower Price Target | Northland Securities | Outperform | $23.00 to $17.00 |
| 2014-10-23 | Reiterated Rating | Barclays | Equal Weight | $19.00 to $20.00 |
| 2014-09-18 | Initiated | Northland Capital | Outperform | $23 |
| 2014-09-18 | Initiated Coverage | Northland Securities | Outperform | $23.00 |
| 2014-07-29 | Boost Price Target | Barclays | Equal Weight | $15.00 to $19.00 |
| 2014-07-29 | Boost Price Target | Robert W. Baird | Equal Weight | $15.00 to $19.00 |
| 2014-05-15 | Reiterated Rating | Cowen and Company | Positive | |
| 2014-04-22 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $20.50 |
| 2014-04-21 | Initiated Coverage | Cantor Fitzgerald | Buy | |
| 2014-04-21 | Initiated Coverage | Wedbush | Outperform | $24.00 |
| 2014-02-21 | Lower Price Target | Barclays | Equal Weight | $19.00 to $15.00 |
| 2014-02-21 | Lower Price Target | JPMorgan Chase & Co. | $22.50 to $21.50 | |
| 2014-02-20 | Reiterated Rating | Cowen and Company | Outperform | |
| 2013-11-04 | Reiterated | Cowen | Outperform | $36 to $24 |
| 2013-11-04 | Lower Price Target | Cowen and Company | Outperform | $36.00 to $24.00 |
| 2013-10-18 | Downgrade | Stephens | Overweight to Underweight | |
| 2013-09-17 | Initiated Coverage | Standpoint Research | Buy | $33.00 |
| 2011-07-08 | Initiated | Barclays Capital | Equal Weight | $41 |
| 2011-04-19 | Initiated | GARP Research | Buy | |
| 2008-07-25 | Downgrade | Davenport | Strong Buy to Buy | $8 |
| 2007-04-27 | Reiterated | Davenport | Strong Buy | $20 to $24 |
| 2016-05-23 | Upgrade | Northland Securities | Market Perform to Outperform | $5.20 to $7.00 |
| 2016-01-05 | Downgrade | Barclays | Equal Weight to Underweight | $12.00 to $4.00 |
| 2016-01-05 | Downgrade | Barclays PLC | Equal Weight to Underweight | $12.00 to $4.00 |
| 2015-12-28 | Downgrade | Northland Securities | Hold | |
| 2015-12-23 | Lower Price Target | Lake Street Capital | Buy | $12.00 to $6.50 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ACTG 71 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Invesco Ltd. | 2.63M |
| OPPENHEIMER FUNDS INC | 2.50M |
| Vanguard Group, Inc | 1.98M |
| Arrowpoint Asset Management, LLC | 1.80M |
| RENAISSANCE TECHNOLOGIES LLC | 1.74M |
| BlackRock Fund Advisors | 1.28M |
| RUSSELL FRANK CO/ | 1.23M |
| BlackRock Institutional Trust Company, N.A. | 1.22M |
| Pacific Ridge Capital Partners, LLC | 1.14M |
| DIMENSIONAL FUND ADVISORS LP | 1.11M |
| BlackRock Inc. | 0.94M |
| CWM, LLC | 0.67M |
| FULLER & THALER ASSET MANAGEMENT, INC. | 0.54M |
| GEODE CAPITAL MANAGEMENT, LLC | 0.53M |
| BRIDGEWAY CAPITAL MANAGEMENT INC | 0.47M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| RYAN PAUL R President & CEO | 0.86% (430891) | ACTG / |
| WALSH FRANK E III | 0.79% (395726) | ACTG / FCCY / |
| HARRIS ROBERT L II Executive Chairman | 0.76% (379609) | ACTG / HPP / |
| GRAZIADIO G LOUIS III | 0.71% (354500) | ACTG / WPT / |
| Vella Matthew President | 0.49% (245884) | ACTG / |
| Key Marvin E CEO | 0.38% (190833) | ACTG / |
| Stewart Robert B Jr President | 0.20% (98643) | ACTG / |
| HAYNES CLAYTON J Sr.V.P, CFO | 0.19% (94667) | ACTG / |
| DEBOOM FRED A | 0.16% (78600) | ACTG / |
| FRYKMAN EDWARD W | 0.15% (73290) | ACTG / ARWR / |
| Lee Dooyong Executive Vice President | 0.14% (69467) | ACTG / |
| Treska Edward Joseph Sr. V.P., G.C., Secretary | 0.11% (56035) | ACTG / |
| Anderson William S. | 0.09% (47370) | ACTG / FCTY / |
UM